Tech Portfolio

Psychology

Cannabinoids (Cannabis): Treatment and prevention of neuropsychiatric disorders

Researcher: Prof. Irit Akirav

Revealing the therapeutic potential of cannabinoids for the prevention and treatment of post-traumatic stress disorder (PTSD), depression and other stress-related disorders.

Background
According to a 2001 World Health Organization report, 450 million people around the world have some form of mental disorder or brain condition. As many as one in four people meet the criteria of a mental disorder at some point in their life, making it a target for more effective and cost-efficient therapies.
Cannabinoids can be studied as a potential therapeutic target for the treatment of disorders that involve stress and anxiety such as PTSD, depression, pain, compulsive disorder, schizophrenia and eating-related disorders.

 

Therapeutic potential of cannabinoids
Prof. Irit Akirav is director of the Laboratory for Learning and Memory in the University of Haifa's Department of Psychology, and chair of the Department of Psychology. Her research focuses on the involvement of the endocannabinoid system in stress, memory and plasticity. One of the main interests in the lab is studying the therapeutic potential of cannabinoids for the treatment of post-traumatic stress disorder (PTSD), depression and other stress-related disorders.

 

Research Status

By employing multidisciplinary approaches which include behavioral, pharmacological, electrophysiological, and molecular techniques Prof. Akirav studies the processes underlying the role of cannabinoids in modulating normal and pathological memory in rat models.

Currently, the research is focused on studying the therapeutic potential of cannabinoids for the treatment of post-traumatic stress disorder (PTSD), depression and other stress-related disorders.

PSTD prevention and treatment: The research team in the Laboratory for Learning and Memory has shown for the first time that enhancing endocannabinoid signaling in the aftermath of exposure to a traumatic event can prevent the development of post-trauma symptoms as well as the stress-induced alterations in plasticity in the brain’s fear circuit. These alterations in plasticity are closely associated with the development of post-trauma symptoms. Moreover, chronic treatment with cannabinoids after the development of PTSD-like symptoms ameliorated these symptoms.
This work extends our understanding of the role of the endocannabinoid system in stress and specifically, the role of this system in the development of PTSD.

Stress: In a series of studies they have also found that cannabinoids can prevent the deteriorating effects of acute and chronic stress on learning and brain plasticity as well as on emotional function.

Contact us for further information.

MMPI®-2 Minnesota Multiphasic Personality Inventory 2

  

Minnesota Multiphasic Personality Inventory®-2 (MMPI®-2)

 

Authors

 

2001 Manual:  James N. Butcher, Ph.D., John R. Graham, Ph.D., Yossef S. Ben-Porath, Ph.D., Auke Tellegen, Ph.D., W. Grant Dahlstrom, Ph.D., and Beverly Kaemmer, Coordinator for the Press

 

2003 RC Scales Test Monograph:  Auke Tellegen, Ph.D.,Yossef S. Ben-Porath, Ph.D., John L. McNulty, Ph.D., Paul A. Arbisi, Ph.D., John R. Graham, Ph.D., and Beverly Kaemmer

 

2009 FBS Test Monograph:  Yossef S. Ben-Porath, Ph.D., John R. Graham, Ph.D., Auke Tellegen, Ph.D.

 

Publisher:  University of Minnesota Press

 

Length:  567 True-False items

 

Administration Time:  60-90 minutes

 

Age:  18 years and older

 

The Minnesota Multiphasic Personality Inventory®-2 (MMPI®-2), a revision of the original MMPI® (1943) was published by the University of Minnesota Press in 1989 and revised in 2001.  Updates were introduced in 2003 (The Restructured Clinical [RC] Scales) and 2006 (The Symptom Validity [FBS] Scale) documented in a test monograph in 2009.  

Relevant to a range of contemporary applications, the MMPI®-2 instrument is the most widely used and widely researched test of adult psychopathology. Used by clinicians to assist with the diagnosis of mental disorders and the selection of appropriate treatment methods, the MMPI®-2 test continues to help meet the assessment needs of mental health professionals in an ever-changing environment.

The MMPI®-2 test’s contemporary normative sample and extensive research base make it the assessment of choice for a wide variety of settings. The test can be used to help:

     Assess major symptoms of social and personal maladjustment.

     Identify suitable candidates for high-risk public safety positions.

     Give a strong empirical foundation for a clinician's expert testimony.

     Assess medical patients and design effective treatment strategies, including chronic pain management.

     Evaluate participants in substance abuse programs and select appropriate treatment approaches.

     Support college and career counseling recommendations.

     Provide valuable insight for marriage and family counseling.

The 567-item MMPI-2 is composed of over 120 scales, including

Validity Indicators, Superlative Self-Presentation Subscales, Clinical Scales, Restructured Clinical (RC) Scales, Content Scales, Content Component Scales, Supplementary Scales, Clinical Subscales (Harris-Lingoes and Social Introversion Subscales).

 

MMPI®-2 SCALES

carmel logo

 

Carmel - University of Haifa, Economic Corporation Ltd. 

Eshkol Tower,
25th floor, Room 2502
University of Haifa
Haifa, 3498838
ISRAEL

Tel: +972-(0)4-8288500
Fax: +972-(0)4-8288499
Email: carmel@univ.haifa.ac.il
Website: carmel-ltd.haifa.ac.il

Contact Us

Please contact us for further information

Please type your name.

Please type your last name

Invalid Input

Invalid email address.

Please type your message